Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Aiming For HIV's Weak Spot - The new generation of gp120 entry inhibitors

A small molecule (green) binds within a cavity on the HIV protein gp120. Amino acid residues that contribute only to binding affinity are colored blue, and those that contribute strongly to binding as well as the protein's conformational change are ...

Published
5 hours ago
From
C&EN - Chemical and Engineering News
FDA Approves New Single-Tablet HIV Regimen, Triumeq

The U.S. Food and Drug Administration (FDA) has approved Triumeq, ViiV Healthcare's single-tablet, triple-combination antiretroviral (ARV) regimen, as a first-line therapy to treat HIV. The tablet is comprised of the integrase inhibitor dolutegravir (Tivicay) plus abacavir and lamivudine (Kivexa/Epzicom) and is the first single-tablet regimen to receive approval that does not contain tenofovir.

Published
26 August 2014
From
Aidsmeds.com
Protein tethers HIV and Ebola to cells

A family of proteins that helps viruses, such as HIV and Ebola, enter a cell also can block the release of those viruses. When HIV-1 or any virus infects a cell, it replicates and spreads to other cells. One type of cellular protein—T cell immunoglobulin and mucin domain, or TIM-1—has previously been shown to promote entry of some highly pathogenic viruses into host cells. Researchers have now discovered that the same protein possesses a unique ability to block the release of such viruses. The findings are published in the Proceedings of the National Academy of Sciences. “This is a surprising finding that provides new insights into our understanding of not only HIV infection, but also that of Ebola and other viruses,” says Shan-Lu Liu, associate professor of molecular microbiology and immunology at University of Missouri.

Published
26 August 2014
From
Futurity
Theraclone Sciences cuts HIV antibodies deal with Gilead

Theraclone Sciences Inc. of Seattle said it's made a deal with Gilead Sciences Inc. that will allow the Foster City-based biotech giant to develop and commercialize Theraclone's neutralizing HIV-antibodies for therapeutic applications in HIV.

Published
31 July 2014
From
San Francisco Business Times (blog)
The Medicines Patent Pool (MPP) broadens collaboration with Gilead Sciences: Signs licence for Phase III medicine tenofovir alafenamide (TAF)

The licence will allow manufacturers in India and China to develop generic versions of TAF for 112 countries that are home to more than 92% of people living with HIV in the developing world.

Published
25 July 2014
From
Medicines Patent Pool
Novel techniques probed in cure research

Two presentations at the 20th International AIDS Conference (AIDS 2014) in Melbourne described new pathways being explored in the search for either a permanent cure for HIV

Published
22 July 2014
By
Gus Cairns
HIV, HCV and TB Pipeline Report

Drugs, diagnostics, vaccines, preventive technologies, research towards a cure, and immune-based and gene therapies in development.

Published
21 July 2014
From
Treatment Action Group & i-Base
Therapy with newer, safer antiretrovirals an option for the majority of HIV-positive patients

The majority of people taking antiretroviral therapy (ART) that includes drugs associated with long-term side-effects may have the option of switching to a novel regimen

Published
11 July 2014
By
Michael Carter
Triumeq® (dolutegravir/abacavir/lamivudine) single-tablet regimen receives positive CHMP opinion in Europe for the treatment of HIV

ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine) for the treatment of HIV infection in adults and adolescents aged 12 years and older and weighing at least 40kg.

Published
30 June 2014
From
Viiv Healthcare press release
Dolutegravir in HIV-1 infection: Added benefit in adult patients

The German Institute for Quality and Efficiency in Health Care (IQWiG) has determined that the new integrase inhibitor drug dolutegravir (Tivicay ®) is of considerable added benefit to treatment-naive patients in comparison with current first-line therapies, and some added benefit to patients who already need to take an integrase inhibitor.

Published
19 June 2014
From
Science Daily
← First12345...77Next →

Filter by country